Michael Vinzenz Knopp

机构：The Ohio State University · ORCID：0000-0001-9543-2962

发表论文 628 篇 · 总被引 21006 次 · h-index 74

代表论文

• Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors (2024 · New England Journal of Medicine · 被引 158)
• BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas (2023 · New England Journal of Medicine · 被引 147)
• Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations (2022 · Journal of Clinical Oncology · 被引 114)
• LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) (2023 · Annals of Oncology · 被引 28)
• Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop (2023 · The Lancet Oncology · 被引 26)
• Multi-vendor multi-site quantitative MRI analysis of cartilage degeneration 10 Years after anterior cruciate ligament reconstruction: MOON-MRI protocol and preliminary results (2022 · Osteoarthritis and Cartilage · 被引 14)